These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 22103746)

  • 21. Overexpression of KCNJ2 in induced pluripotent stem cell-derived cardiomyocytes for the assessment of QT-prolonging drugs.
    Li M; Kanda Y; Ashihara T; Sasano T; Nakai Y; Kodama M; Hayashi E; Sekino Y; Furukawa T; Kurokawa J
    J Pharmacol Sci; 2017 Jun; 134(2):75-85. PubMed ID: 28615142
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Use of Ratiometric Fluorescence Measurements of the Voltage Sensitive Dye Di-4-ANEPPS to Examine Action Potential Characteristics and Drug Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes.
    Hortigon-Vinagre MP; Zamora V; Burton FL; Green J; Gintant GA; Smith GL
    Toxicol Sci; 2016 Dec; 154(2):320-331. PubMed ID: 27621282
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.
    Kitaguchi T; Moriyama Y; Taniguchi T; Ojima A; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Morita M; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Tanaka K; Washio I; Miyamoto N
    J Pharmacol Toxicol Methods; 2016; 78():93-102. PubMed ID: 26657830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system.
    Kanda Y; Yamazaki D; Kurokawa J; Inutsuka T; Sekino Y
    J Pharmacol Toxicol Methods; 2016; 81():196-200. PubMed ID: 27369811
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes as Models for Cardiac Channelopathies: A Primer for Non-Electrophysiologists.
    Garg P; Garg V; Shrestha R; Sanguinetti MC; Kamp TJ; Wu JC
    Circ Res; 2018 Jul; 123(2):224-243. PubMed ID: 29976690
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The influence of hERG1a and hERG1b isoforms on drug safety screening in iPSC-CMs.
    Goversen B; Jonsson MK; van den Heuvel NH; Rijken R; Vos MA; van Veen TA; de Boer TP
    Prog Biophys Mol Biol; 2019 Dec; 149():86-98. PubMed ID: 30826123
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of the heart's electrical properties by the anticonvulsant drug retigabine.
    Rubi L; Kovar M; Zebedin-Brandl E; Koenig X; Dominguez-Rodriguez M; Todt H; Kubista H; Boehm S; Hilber K
    Toxicol Appl Pharmacol; 2017 Aug; 329():309-317. PubMed ID: 28641963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.
    Pfeiffer ER; Vega R; McDonough PM; Price JH; Whittaker R
    J Pharmacol Toxicol Methods; 2016; 81():263-73. PubMed ID: 27095424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
    Qu Y; Vargas HM
    Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of Batch Variations in Induced Pluripotent Stem Cell-Derived Human Cardiomyocytes from 2 Major Suppliers.
    Huo J; Kamalakar A; Yang X; Word B; Stockbridge N; Lyn-Cook B; Pang L
    Toxicol Sci; 2017 Mar; 156(1):25-38. PubMed ID: 28031415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Improving reliability and reducing costs of cardiotoxicity assessments using laser-induced cell poration on microelectrode arrays.
    Iachetta G; Colistra N; Melle G; Deleye L; Tantussi F; De Angelis F; Dipalo M
    Toxicol Appl Pharmacol; 2021 May; 418():115480. PubMed ID: 33689843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.
    Talbert DR; Doherty KR; Trusk PB; Moran DM; Shell SA; Bacus S
    Toxicol Sci; 2015 Jan; 143(1):147-55. PubMed ID: 25304212
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug-induced hERG block and long QT syndrome.
    Witchel HJ
    Cardiovasc Ther; 2011 Aug; 29(4):251-9. PubMed ID: 20406244
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In silico prediction of the chemical block of human ether-a-go-go-related gene (hERG) K+ current.
    Inanobe A; Kamiya N; Murakami S; Fukunishi Y; Nakamura H; Kurachi Y
    J Physiol Sci; 2008 Dec; 58(7):459-70. PubMed ID: 19032804
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Exploration of human, rat, and rabbit embryonic cardiomyocytes suggests K-channel block as a common teratogenic mechanism.
    Danielsson C; Brask J; Sköld AC; Genead R; Andersson A; Andersson U; Stockling K; Pehrson R; Grinnemo KH; Salari S; Hellmold H; Danielsson B; Sylvén C; Elinder F
    Cardiovasc Res; 2013 Jan; 97(1):23-32. PubMed ID: 22997158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blockade of the I(Ks) potassium channel: an overlooked cardiovascular liability in drug safety screening?
    Towart R; Linders JT; Hermans AN; Rohrbacher J; van der Linde HJ; Ercken M; Cik M; Roevens P; Teisman A; Gallacher DJ
    J Pharmacol Toxicol Methods; 2009; 60(1):1-10. PubMed ID: 19439185
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modeling Reentry in the Short QT Syndrome With Human-Induced Pluripotent Stem Cell-Derived Cardiac Cell Sheets.
    Shinnawi R; Shaheen N; Huber I; Shiti A; Arbel G; Gepstein A; Ballan N; Setter N; Tijsen AJ; Borggrefe M; Gepstein L
    J Am Coll Cardiol; 2019 May; 73(18):2310-2324. PubMed ID: 31072576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multi-parametric assessment of cardiomyocyte excitation-contraction coupling using impedance and field potential recording: A tool for cardiac safety assessment.
    Zhang X; Guo L; Zeng H; White SL; Furniss M; Balasubramanian B; Lis E; Lagrutta A; Sannajust F; Zhao LL; Xi B; Wang X; Davis M; Abassi YA
    J Pharmacol Toxicol Methods; 2016; 81():201-16. PubMed ID: 27282640
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation.
    Nozaki Y; Honda Y; Tsujimoto S; Watanabe H; Kunimatsu T; Funabashi H
    Toxicol Appl Pharmacol; 2014 Jul; 278(1):72-7. PubMed ID: 24742750
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug-induced functional cardiotoxicity screening in stem cell-derived human and mouse cardiomyocytes: effects of reference compounds.
    Himmel HM
    J Pharmacol Toxicol Methods; 2013; 68(1):97-111. PubMed ID: 23702537
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.